(917) 310-3371
An infectious-disease visit starts with symptoms, exposure and severity rather than the name of a new medicine. Recent travel, an outbreak contact, immune suppression and pregnancy can change testing and care.
Xocova (ensitrelvir) is FDA-approved for COVID-19 post-exposure prophylaxis in adults and adolescents aged 12 or older. It is a five-day oral regimen begun as soon as possible and within 72 hours after contact with someone who has COVID-19. This US indication differs from treatment of established illness. The clinician verifies pregnancy status and reviews all medicines. Certain CYP3A substrates and strong inducers are contraindicated. The label advises effective contraception during use and for two weeks after the final dose, and no breastfeeding during that period. Severe hypersensitivity needs urgent care. Ask whether post-exposure prevention is appropriate and available; do not borrow a treatment course or stop interacting drugs yourself. Approval does not establish clinic stock or insurance payment. If symptoms develop, contact the clinician for a new assessment.
FDA approval and emergency authorization are distinct. Paxlovid has an approved adult indication and an EUA adolescent pathway; Veklury is approved, while Lagevrio remains an adult EUA alternative under defined conditions. FDA's current notice schedules termination of COVID drug and biologic EUAs for June 29, 2027. They did not all end in June 2026. Eligibility, the current product instructions and any later regulatory change must be checked when prescribing. Xocova has a separate approved post-exposure prevention indication and should not be described as the same treatment choice. Confirm the actual drug, purpose and formulation with the prescribing clinician.
An infectious-disease visit starts with symptoms, exposure and severity rather than the name of a new medicine. Recent travel, an outbreak contact, immune suppression and pregnancy can change testing and care. For COVID-19, people at higher risk of severe illness may benefit from time-sensitive antiviral treatment while symptoms are still mild or moderate. Contact a clinician promptly with the symptom-onset date; do not wait for severe illness to discuss treatment.
COVID antivirals inhibit viral replication. They differ in route, eligibility, initiation window and interactions. Paxlovid is an oral nirmatrelvir/ritonavir course. Veklury is intravenous remdesivir. Lagevrio is oral molnupiravir authorized only when other approved or authorized options are not accessible or clinically appropriate. None is a general treatment for every emerging infection or an assurance against hospitalization.
The clinician assesses confirmed or suspected COVID according to current testing requirements, risk of progression and whether outpatient care is appropriate. Paxlovid is FDA-approved for eligible adults; its adolescent pathway is EUA for age 12 or older and at least 40 kg. Veklury’s current label includes pediatric patients from birth weighing at least 1.5 kg, but pediatric administration requires the appropriate clinical setting. Lagevrio is authorized for adults only and is not FDA-approved. Pregnancy and reproductive precautions differ across products.
Describe when symptoms began, testing, breathing symptoms and risk factors. Breathing difficulty, persistent chest pain, confusion or inability to stay awake needs emergency assessment, not a routine antiviral booking.
Ritonavir has major interaction risks. Include seizure drugs, transplant medicines, statins, blood thinners, HIV medicines, supplements and any recently stopped drugs. Kidney function determines the Paxlovid regimen; the current US instructions include a severe-renal regimen, so an older blanket exclusion is inaccurate.
Paxlovid and Lagevrio must start within five days of symptom onset. Outpatient remdesivir starts within seven days and is given on three consecutive days. The clinician considers whether an infusion service can complete the course and perform required safety checks.
Confirm how to obtain the full treatment, whom to call for adverse effects and when worsening symptoms require reassessment. Guidance for work, infection precautions and other infections is separate from the medication prescription.
Bring the test result, onset date, vaccination and relevant medical history, pregnancy/breastfeeding information and all current medicines. Do not hold, restart or change interacting medicines on your own to qualify for Paxlovid. An expert may manage an interaction or select a different antiviral. If remdesivir is chosen, liver tests and prothrombin time are checked before treatment and monitored as appropriate.
Paxlovid’s boxed warning concerns potentially severe or fatal drug interactions. Severe hepatic impairment and specific interacting drugs affect suitability. Remdesivir requires an infusion setting able to handle serious hypersensitivity reactions; it can affect liver enzymes. Molnupiravir has embryo-fetal and reproductive precautions and is not for children. The prescriber provides the applicable contraception and breastfeeding advice. A new product’s regulatory status does not override these safety requirements.
Complete the prescribed course and contact the team for intolerance, access failure or worsening illness. Rebound symptoms can occur after COVID with or without antiviral treatment; tell the clinician rather than self-starting a second course. Persistent symptoms need assessment of other causes and appropriate follow-up. Treatment does not establish that you are immediately noninfectious or ready for every work setting.
Confirm that the receiving service can assess you within the treatment window, fill the oral prescription or arrange the full infusion sequence. Check that the chosen service actually offers the prescribed treatment route and can arrange it on time. Seek a suitable alternative service promptly if time-sensitive care cannot be arranged.
No. Current US instructions include renal-adjusted regimens, including severe renal impairment. The prescriber must determine kidney function and the correct package/regimen; do not split or alter a standard course yourself.
No. Transplant medicines can interact dangerously with ritonavir. Contact the transplant and prescribing teams for expert management or an alternative antiviral. Do not use a forum holding/restart protocol.
No. Veklury is intravenous. Eligible nonhospitalized patients receive a three-day course started within seven days of symptoms, with safety testing and an appropriate infusion setting. Availability must be confirmed.
No. It is EUA-authorized for eligible adults when other options are inaccessible or inappropriate, and it is not FDA-approved. Its pregnancy and reproductive precautions require review.
Contact a clinician early if you may be at higher risk. The treatment initiation windows are short. Severe breathing or chest symptoms require urgent assessment irrespective of an antiviral plan.
Ebola disease is a serious illness caused by an orthoebolavirus. It requires a different assessment and care pathway from COVID-19. If you develop symptoms after recent travel to an Ebola-affected area or a relevant exposure, separate yourself from others and contact your health department promptly. Describe the travel, exposure and symptoms, and follow its instructions. Do not travel while sick unless a health official clears you. Call ahead before going to a healthcare facility so it can prepare. If you need urgent medical care and cannot reach the health department or a healthcare provider, call 911 and explain the exposure. A routine clinic booking does not establish Ebola testing or treatment capability.
Choose the right appointment type to continue.
